Barinthus Biotherapeutics plc (NASDAQ:BRNS) Short Interest Up 39.6% in April

Barinthus Biotherapeutics plc (NASDAQ:BRNS) was the recipient of a significant increase in short interest in the month of April. As of April 15th, there was short interest totalling 14,100 shares, an increase of 39.6% from the March 31st total of 10,100 shares. Based on an average daily volume of 22,000 shares, the short-interest ratio is presently 0.6 days. Currently, 0.0% of the shares of the company are sold short.

Barinthus Biotherapeutics Stock Up 3.6 %

BRNS traded up $0.09 on Monday, hitting $2.59. 4,158 shares of the company were exchanged, compared to its average volume of 18,873. Barinthus Biotherapeutics has a fifty-two week low of $1.64 and a fifty-two week high of $5.10. The firm has a market capitalization of $100.80 million, a price-to-earnings ratio of -1.35 and a beta of -0.52. The business has a fifty day moving average price of $2.69.

Barinthus Biotherapeutics (NASDAQ:BRNS) last released its quarterly earnings results on Wednesday, March 20th. The company reported ($0.45) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.55) by $0.10. On average, sell-side analysts predict that Barinthus Biotherapeutics will post -2.6 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several analysts have recently commented on BRNS shares. William Blair reissued an “outperform” rating on shares of Barinthus Biotherapeutics in a report on Monday, January 8th. HC Wainwright reiterated a “buy” rating and issued a $8.00 price objective on shares of Barinthus Biotherapeutics in a research report on Friday, April 19th.

About Barinthus Biotherapeutics

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.